Abstract
Preterm birth is the leading cause of perinatal morbidity and mortality. Fetal fibronectin (fFN), a glycoprotein in the extracellular matrix of the amniotic membranes, is the most powerful biomarker for predicting the risk of preterm birth. Biosensors using the surface plasmon resonance (SPR) response are potentially useful in quantitatively measuring molecules. We established a standard calibration curve of SPR intensity against fFN concentration and used the SPR-based biosensor to detect fFN concentrations in the cervicovaginal secretions of pregnant women between 22 and 34 weeks of gestation. The calibration curve extends from 0.5 ng/mL to 100 ng/mL with an excellent correlation (R2 = 0.985) based on standard fFN samples. A cutoff value of 50 ng/mL fFN concentration in commercial ELISA kits corresponds to a relative intensity of 17 arbitrary units (a.u.) in SPR. Thirty-two pregnant women were analyzed in our study. In 11 women, the SPR relative intensity was greater than or equal to 17 a.u., and in 21 women, the SPR relative intensity was less than 17 a.u. There were significant differences between the two groups in regular uterine contractions (p = 0.040), hospitalization for tocolysis (p = 0.049), and delivery weeks (p = 0.043). Our prospective study concluded that SPR-based biosensors can quantitatively measure fFN concentrations. These results reveal the potential utility of SPR-based biosensors in predicting the risk of preterm birth.
Highlights
Preterm birth is defined by the World Health Organization as delivery at less than 37 gestational weeks [1]
surface plasmon resonance (SPR) relative intensities were measured with concentrations of 0.5, 1, 5, 10, 50, and 100 ng/mL of fetal fibronectin (fFN) antigen over a chip fixed with 0.5 μg/mL fFN antibody
The SPR intensity corresponding to the critical concentration of 50 ng/mL in the fFN enzyme-linked immunosorbent assay (ELISA) assay for the risk evaluation of preterm birth was 17 a.u
Summary
Preterm birth is defined by the World Health Organization as delivery at less than 37 gestational weeks [1]. It is the main cause of perinatal morbidity and mortality, with an incidence of 5 to 13% in developed countries, and it accounts for nearly 70% of neonatal deaths and 50% of neurological disabilities [2,3,4,5]. (IL-6), monocyte chemotactic protein-1 (MCP-1), phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1), and matrix metalloproteinase-8 (MMP-8) [6,7,8,9,10] Of these biomarkers, the most powerful is fFN because of its high negative predictive value: only 1% of pregnant women with a negative fFN result deliver within the week [2,11,12,13]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
